• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受抗病毒治疗的慢性乙型肝炎患者及实现HBsAg清除患者血清乙肝病毒前基因组RNA动力学的临床意义

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss.

作者信息

Wu I-Chin, Liu Wen-Chun, Chiu Yen-Cheng, Chiu Hung-Chih, Cheng Pin-Nan, Chang Ting-Tsung

机构信息

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.

出版信息

Microorganisms. 2021 May 26;9(6):1146. doi: 10.3390/microorganisms9061146.

DOI:10.3390/microorganisms9061146
PMID:34073483
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8229518/
Abstract

Serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) is correlated with covalently closed circular DNA. We aimed to investigate the utility of serum HBV pgRNA in chronic hepatitis B patients receiving nucleos(t)ide analogue treatment and those achieving HBsAg loss. One hundred and eighty-five patients were enrolled for studying long-term HBV pgRNA kinetics during treatment. Twenty patients achieving HBsAg loss after treatment were enrolled for examining HBV pgRNA kinetics around HBsAg loss. HBV pgRNA significantly decreased in the high baseline HBV pgRNA (≥6 log copies/mL) group but significantly increased in the low baseline HBV pgRNA (<4 log copies/mL) group after 3-month entecavir treatment. Among the 20 patients achieving HBsAg loss, 13 (65%) patients had serum HBV pgRNA higher than the limit of detection (LOD, 1466 copies/mL) when they achieved HBsAg loss. Finally, all 20 patients had HBV pgRNA going below the LOD within 3 years after achieving HBsAg loss. In conclusion, baseline serum HBV pgRNA alone is insufficient for predicting the trajectory of HBV pgRNA. Most patients still had HBV pgRNA higher than the LOD when they achieved HBsAg loss. Further studies on HBV pgRNA kinetics around HBsAg loss would provide an enhanced basis for further applications of HBV pgRNA.

摘要

血清乙型肝炎病毒(HBV)前基因组RNA(pgRNA)与共价闭合环状DNA相关。我们旨在研究血清HBV pgRNA在接受核苷(酸)类似物治疗的慢性乙型肝炎患者以及实现HBsAg清除的患者中的应用价值。招募了185名患者用于研究治疗期间的长期HBV pgRNA动力学。招募了20名治疗后实现HBsAg清除的患者用于检查HBsAg清除前后的HBV pgRNA动力学。在高基线HBV pgRNA(≥6 log拷贝/mL)组中,恩替卡韦治疗3个月后HBV pgRNA显著下降,但在低基线HBV pgRNA(<4 log拷贝/mL)组中显著上升。在20名实现HBsAg清除的患者中,13名(65%)患者在实现HBsAg清除时血清HBV pgRNA高于检测下限(LOD,1466拷贝/mL)。最后,所有20名患者在实现HBsAg清除后的3年内HBV pgRNA均降至LOD以下。总之,仅基线血清HBV pgRNA不足以预测HBV pgRNA的变化轨迹。大多数患者在实现HBsAg清除时HBV pgRNA仍高于LOD。对HBsAg清除前后HBV pgRNA动力学的进一步研究将为HBV pgRNA的进一步应用提供更好的基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/65c1ce311974/microorganisms-09-01146-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/6a7bc46fdd19/microorganisms-09-01146-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/d0962b6cffb3/microorganisms-09-01146-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/87efcfdecbf7/microorganisms-09-01146-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/5847ad7c7f76/microorganisms-09-01146-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/40013d356655/microorganisms-09-01146-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/c4fed0b0811a/microorganisms-09-01146-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/65c1ce311974/microorganisms-09-01146-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/6a7bc46fdd19/microorganisms-09-01146-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/d0962b6cffb3/microorganisms-09-01146-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/87efcfdecbf7/microorganisms-09-01146-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/5847ad7c7f76/microorganisms-09-01146-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/40013d356655/microorganisms-09-01146-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/c4fed0b0811a/microorganisms-09-01146-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94f/8229518/65c1ce311974/microorganisms-09-01146-g007.jpg

相似文献

1
Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss.接受抗病毒治疗的慢性乙型肝炎患者及实现HBsAg清除患者血清乙肝病毒前基因组RNA动力学的临床意义
Microorganisms. 2021 May 26;9(6):1146. doi: 10.3390/microorganisms9061146.
2
Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes.检测不同临床结局的乙型肝炎病毒感染者血清前基因组 RNA 的诊断价值。
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01275-19.
3
Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.长期核苷(酸)类似物治疗慢性乙型肝炎时共价闭合环状 DNA 的减少。
J Hepatol. 2017 Feb;66(2):275-281. doi: 10.1016/j.jhep.2016.08.022. Epub 2016 Sep 14.
4
Dynamics of Hepatitis B Virus Pregenomic RNA in Chronic Hepatitis B Patients With Antiviral Therapy Over 9 Years.9年以上抗病毒治疗的慢性乙型肝炎患者中乙型肝炎病毒前基因组RNA的动态变化
Front Med (Lausanne). 2022 Apr 29;9:851717. doi: 10.3389/fmed.2022.851717. eCollection 2022.
5
[Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].[长期抗病毒治疗的慢性乙型肝炎患者血清乙肝病毒前基因组RNA谱]
Zhonghua Gan Zang Bing Za Zhi. 2024 Jan 20;32(1):16-21. doi: 10.3760/cma.j.cn501113-20230814-00054.
6
Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy.抗病毒治疗 5 年后乙型肝炎病毒前基因组 RNA 状态的影响因素及其病毒学意义。
Int J Infect Dis. 2021 Apr;105:418-423. doi: 10.1016/j.ijid.2021.02.116. Epub 2021 Mar 3.
7
Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients.中国慢性乙型肝炎患者血清 HBV 前基因组 RNA 水平的分布及其影响因素。
J Med Virol. 2021 Jun;93(6):3688-3696. doi: 10.1002/jmv.26529. Epub 2020 Oct 5.
8
[The relationship between serum HBV pgRNA and antigen status in patients with chronic hepatitis B after long-term nucleotide analogues treatment].[长期核苷类似物治疗后慢性乙型肝炎患者血清HBV pgRNA与抗原状态的关系]
Zhonghua Gan Zang Bing Za Zhi. 2021 Aug 20;29(8):766-770. doi: 10.3760/cma.j.cn501113-20200303-00083.
9
Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.慢性和急性感染期间核苷(酸)类似物治疗或未治疗患者的乙型肝炎病毒血清 DNA 和 RNA 水平。
Hepatology. 2018 Dec;68(6):2106-2117. doi: 10.1002/hep.30082. Epub 2018 Sep 22.
10
[Predictive Value of Baseline Serum Marker Levels for the Effect of Interferon Therapy in Patients With Chronic Hepatitis B].[基线血清标志物水平对慢性乙型肝炎患者干扰素治疗效果的预测价值]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Mar 20;55(2):383-390. doi: 10.12182/20240360105.

引用本文的文献

1
Effect analysis of entecavir on serum hyaluronic acid, laminin and IV collagen in the treatment of hepatitis B E-antigen-positive chronic hepatitis B.恩替卡韦治疗乙肝e抗原阳性慢性乙型肝炎对血清透明质酸、层粘连蛋白及IV型胶原的疗效分析
Afr Health Sci. 2024 Dec;24(4):38-42. doi: 10.4314/ahs.v24i4.6.
2
Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.在替诺福韦治疗期间,HIV/HBV 合并感染和乙型肝炎表面抗原丢失的患者中循环 HBV RNA 和乙型肝炎核心相关抗原的轨迹。
J Infect Dis. 2024 Oct 16;230(4):e954-e963. doi: 10.1093/infdis/jiae189.
3

本文引用的文献

1
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load.血清乙型肝炎核心相关抗原水平可分层慢性乙型肝炎病毒载量中等患者的疾病进展风险。
Aliment Pharmacol Ther. 2021 Apr;53(8):908-918. doi: 10.1111/apt.16266. Epub 2021 Jan 19.
2
Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed.核苷(酸)类似物治疗下的早期乙肝病毒RNA动力学可能揭示乙肝病毒RNA动态变化及核苷(酸)类似物作用模式的新见解——需要更详细的动力学研究。
J Viral Hepat. 2021 Apr;28(4):687-688. doi: 10.1111/jvh.13463. Epub 2021 Jan 15.
3
The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
乙肝生物标志物对HBV/HCV合并感染患者直接抗病毒治疗后HBV再激活的预测作用
Viruses. 2022 Aug 18;14(8):1812. doi: 10.3390/v14081812.
4
Dynamics of Hepatitis B Virus Pregenomic RNA in Chronic Hepatitis B Patients With Antiviral Therapy Over 9 Years.9年以上抗病毒治疗的慢性乙型肝炎患者中乙型肝炎病毒前基因组RNA的动态变化
Front Med (Lausanne). 2022 Apr 29;9:851717. doi: 10.3389/fmed.2022.851717. eCollection 2022.
5
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV.HBV 和 HCV 合并感染患者中 HCV 病毒血症对 HBV 生物标志物的影响。
BMC Infect Dis. 2022 Apr 9;22(1):351. doi: 10.1186/s12879-022-07326-1.
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
抗病毒治疗时 HBsAg 丢失的比较生物标志物显示定量 HBsAg(qHBsAg)具有主导影响。
Aliment Pharmacol Ther. 2021 Jan;53(1):172-182. doi: 10.1111/apt.16149. Epub 2020 Nov 7.
4
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.慢性乙型肝炎不同疾病阶段和抗病毒治疗患者的 HBV RNA 谱。
Hepatology. 2021 Jun;73(6):2167-2179. doi: 10.1002/hep.31616.
5
What drives the dynamics of HBV RNA during treatment?HBV RNA 在治疗过程中的动态变化受什么驱动?
J Viral Hepat. 2021 Feb;28(2):383-392. doi: 10.1111/jvh.13425. Epub 2020 Nov 2.
6
Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.血清 HBV RNA 和乙型肝炎表面抗原水平在确定适合恩替卡韦停药的亚洲慢性乙型肝炎患者中的作用。
Gut. 2021 Apr;70(4):775-783. doi: 10.1136/gutjnl-2020-321116. Epub 2020 Aug 5.
7
Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy.接受核苷(酸)类似物治疗的慢性乙型肝炎患者中,循环中的乙肝病毒前基因组RNA主要为全长形式。
Clin Infect Dis. 2021 Jun 1;72(11):2029-2031. doi: 10.1093/cid/ciaa1015.
8
Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.HBsAg 水平低于 100IU/mL 的患者停止使用恩替卡韦或替诺福韦后 HBV 复发的发生率及相关因素。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2803-2812.e2. doi: 10.1016/j.cgh.2020.04.037. Epub 2020 Apr 29.
9
Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.乙型肝炎病毒 RNA 与乙型肝炎核心相关抗原联合检测:乙型肝炎 e 抗原阳性慢性乙型肝炎患者安全停用核苷(酸)类似物的指导意见。
J Infect Dis. 2020 Jul 23;222(4):611-618. doi: 10.1093/infdis/jiaa136.
10
Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.超敏 HBsAg 检测可诊断淋巴瘤患者接受利妥昔单抗治疗后的乙型肝炎病毒再激活。
J Hepatol. 2020 Aug;73(2):285-293. doi: 10.1016/j.jhep.2020.03.009. Epub 2020 Mar 17.